Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Pharma
ESMO: Datroway data edge out Trodelvy in first TROP2 face-off
While control arm crossover may explain the lack of an early survival showing for Trodelvy, it cannot explain another weak point in the drug's data.
Angus Liuu
Oct 19, 2025 2:30am
AZ, Daiichi's Datroway scores overall survival win in TNBC
Oct 6, 2025 10:48am
Gilead bolsters Trodelvy with first-line breast cancer win
May 31, 2025 8:00am
Gilead's Trodelvy chalks up another phase 3 breast cancer win
May 23, 2025 10:10am
AstraZeneca's Truqap falls short in another phase 3 trial
Apr 29, 2025 3:26pm
Gilead's Trodelvy-Keytruda proposal hits goal in first-line TNBC
Apr 21, 2025 11:29am
